Skip to main content
OpenTrials
Recruiting

NCT Number: NCT05962346

Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

The purpose of this research is to gather information on the safety and effectiveness of a procedure called Fetoscopic Endoluminal Tracheal Occlusion (FETO) at Mayo Clinic. The intent of the FETO procedure is to improve development of the lungs in fetuses diagnosed with severe congenital diaphragmatic hernia (CDH).

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year–50 year

Sex eligibility

Female

Study type

Interventional

Phase

Not applicable

Primary location

Mayo Clinic Minnesota

Rochester, Minnesota, 55905, United States

Location status: Recruiting

Location contact

Mauro H. Schenone, MD

CONTACT

507-293-4390

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Singleton pregnancy
  • Normal fetal karyotype or microarray. Results by fluorescence in situ hybridization (FISH) will be acceptable if the patient is > 26 weeks
  • Isolated severe left CDH with O/E LHR < 25% )
  • Gestation age at enrollment prior to 29 wks plus 6 days.
  • Pulmonary hypoplasia with ultrasound O/E LHR < 25% (measured at 18 0/7 to 29 5/7 weeks) at the time of surgery.
  • Gestational age at FETO procedure 27 weeks 0 days to 29 weeks 6 days as determined by clinical information (LMP) and evaluation of first ultrasound
  • Patient meets psychosocial criteria: able to reside within 30 minutes of Mayo Clinic, Rochester and able to comply with the travel for the follow-up requirements of the trial; patient has a support person (e.g. spouse, partner, mother) available to stay with the patient for the duration of the pregnancy at Mayo Clinic
  • Patient is willing and able to give informed consent
  • Appropriate multi-disciplinary counseling performed with maternal-fetal medicine, neonatology, pediatric surgery, genetics, pediatric otolaryngology (ENT)

Exclusion criteria

  • Multi-fetal pregnancy
  • History of natural rubber latex allergy
  • Preterm labor, cervix shortened (<20 mm) at enrollment or within 24 hours of FETO balloon insertion procedure) or uterine anomaly strongly predisposing to preterm labor
  • Psychosocial ineligibility, precluding consent: inability to reside within 30 minutes of Mayo Clinic, Rochester and inability to comply with the travel for the follow-up requirements of the trial; patient does not have a support person (e.g. spouse, partner, mother) available to stay with the patient for the duration of the pregnancy at Mayo Clinic
  • Right sided CDH or bilateral CDH, isolated left sided with O/E LHR >25% measured at 18 0/7 to 29 6/7 weeks) as determined by ultrasound
  • Additional fetal anomaly and chromosomal abnormalities by ultrasound, MRI, or echocardiogram that will significantly worsen prognosis. No cases will be removed post hoc if abnormalities are discovered in the course of post-operative monitoring
  • Maternal contraindication to fetoscopic surgery
  • History of incompetent cervix with or without cerclage
  • Placental abnormalities (previa, abruption, accreta) known at time of enrollment
  • Maternal-fetal Rh isoimmunization, Kell sensitization or neonatal alloimmune thrombocytopenia affecting the current pregnancy
  • Maternal HIV, Hepatitis-B, Hepatitis-C status positive.
  • Uterine anomaly such as large or multiple fibroids or mullerian duct abnormality that will make the procedure technically unfeasible
  • No safe or technically feasible fetoscopic approach to balloon placement
  • Participation in another intervention study that influences maternal and fetal morbidity and mortality or participation in this trial in a previous pregnancy

Treatment and study plan

BALT GOLDBALL 2 detachable latex ballon

Device

Inflated with fluid in the fetal trachea and provide with the occlusion necessary to promote lung growth.

BALTACCIBDPE100 Microcatheter

Device

Used to deliver the detachable balloon

Storz fetoscopic operating sheath and miniature telescope/fetoscope

Device

Used to percutaneously enter though the maternal abdominal wall, uterus and into the amniotic cavity, fetal mouth, pharynx, larynx, into the trachea where the delivery catheter will be used to deliver the detachable balloon that will provide with the tracheal occlusion.

Primary outcomes

  1. Technical success of the balloon placement procedure

    Time frame: Up to 29 weeks gestation

    The number of successful balloon placement procedures defined as balloon was correctly inflated and placed/secured in the trachea.

  2. Technical success of balloon retrieval procedure

    Time frame: Up to 34 weeks gestation

    The number of successful balloon retrieval procedure defined as antenatal removal of the balloon.

  3. Operative times

    Time frame: Up to 34 weeks gestation

    FETO placement and release operative times reported in minutes

  4. Frequency of unplanned balloon removal

    Time frame: Up to 34 weeks gestation

    The frequency of non-emergent and emergent completion of FETO release (unplanned balloon removal)

  5. Number of incidences of maternal complications

    Time frame: Up to 41 weeks gestation

    Maternal complications including preterm labor, premature rupture of membranes, oligohydramnios, polyhydramnios, chorioamnionitis

  6. Gestational Age at Delivery

    Time frame: Up to 41 weeks gestation

    Gestation Age reported at time of delivery

Secondary outcomes

  1. Fetal Lung Growth as measured via Fetal Lung Volume

    Time frame: Up to 24 months post partum

    Fetal Lung Volume as measured via ultrasound

  2. Fetal Lung Growth as measured via LHR

    Time frame: Up to 24 months post partum

    Lung area to head circumference Ratio (LHR) as measured via ultrasound

  3. Fetal Survival

    Time frame: Up to 6 months post partum

    Survival at 30 days, discharge from the hospital and at 6 months if still hospitalized

  4. Fetal Oxygen Dependency

    Time frame: Up to 24 months post partum

    Oxygen dependency graded as none, mild, moderate, severe as assessed by treating physician

  5. Occurrence of severe pulmonary hypertension

    Time frame: Up to 24 months post partum

    Number of occurrence of severe pulmonary hypertension in infants based on echocardiogram

  6. ECMO Support

    Time frame: Up to 24 months post partum

    Number of infants reported that required Extracorporeal membrane oxygenation (ECMO) support

  7. Number of days in NICU

    Time frame: Up to 24 months post partum

    Number of days infant was in neonatal intensive care unit

  8. Number of days of ventilator support

    Time frame: Up to 24 months post partum

    Number of reported days infants required ventilator support

  9. Number of periventricular leukomalacia at < 2 months postnatally

    Time frame: Up to 2 months post partum

    Number of infants reported presence of periventricular leukomalacia at < 2 months postnatally

  10. Number of infant complications

    Time frame: Up to 24 months post partum

    Number of infants reporting the presence of: neonatal sepsis, intraventricular hemorrhage (grade 3 or higher), retinopathy of prematurity (grade 3 or higher) or gastro-esophageal reflux

  11. Use of patch or muscle flap

    Time frame: Up to 24 months post partum

    Number of infants reported to require the use of patch or muscle flap

  12. Maternal hospitalization

    Time frame: Up to 24 months post partum

    Number of reported days of maternal hospitalization

  13. Route of delivery

    Time frame: Day 1 (post partum)

    Number of participants that delivered vaginally and via caesarean section

Sponsors and collaborators

Lead sponsor

Mauro H. Schenone

Other

Registry information

Official study title

Pilot Trial of Fetoscopic Endoluminal Tracheal Occlusion for Severe Left Congenital Diaphragmatic Hernia

Acronym: FETO

Important dates

Study start
2026
Primary completion
2043
Study completion
2043
First posted
Jul 27, 2023
Registry last updated
Mar 19, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.